Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer (BEVERLY)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02633189 |
|
Recruitment Status :
Active, not recruiting
First Posted : December 17, 2015
Last Update Posted : March 24, 2023
|
Sponsor:
National Cancer Institute, Naples
Information provided by (Responsible Party):
National Cancer Institute, Naples
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to test whether the combination of bevacizumab and erlotinib can prolong progression free survival as compared with erlotinib alone as first-line treatment in patients with non small cell lung cancer (NSCLC) with activating mutation of EGFR.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Non-squamous Non-small Cell Lung Cancer | Drug: Erlotinib Drug: Bevacizumab | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 200 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized Open-label Phase 3 Trial Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer |
| Actual Study Start Date : | April 2016 |
| Estimated Primary Completion Date : | December 2023 |
| Estimated Study Completion Date : | July 2024 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Lung cancer
MedlinePlus related topics:
Lung Cancer
| Arm | Intervention/treatment |
|---|---|
| Experimental: erlotinib and bevacizumab |
Drug: Erlotinib
given orally 150 mg daily Drug: Bevacizumab 15 mg/kg intravenously every 21 days. |
| Active Comparator: erlotinib |
Drug: Erlotinib
given orally 150 mg daily |
Primary Outcome Measures :
- progression free survival [ Time Frame: up to 2 years ]as determined by investigator
- progression free survival [ Time Frame: up to 2 years ]as determined by an independent central review board blinded to study treatment
Secondary Outcome Measures :
- overall survival [ Time Frame: 1 year ]
- changes in quality of life scores from baseline [ Time Frame: up to 2 years ]
- number of patients with complete and partial responses , investigator assessed [ Time Frame: 6 months ]
- number of patients with complete and partial responses , centrally reviewed [ Time Frame: 6 months ]
- worst grade toxicity per patient [ Time Frame: up to one year ]
- progression free survival according to type of EGFR mutation (exon 19del, exon 21L858R, other) [ Time Frame: 2 years ]
Other Outcome Measures:
- number and type of EGFR mutations in plasma samples [ Time Frame: up to 2 years ]samples taken at baseline, 6 weeks, 6 months, and at progression
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age ≥18 years
- Histological documentation of primary non squamous lung carcinoma
- Stage IV or IIIB disease with supraclavicular metastatic nodes (according to TNM 7th edition)
- Activating epidermal growth factor receptor mutation (exon19 deletion or exon 21 L858R mutation or other activating/sensitizing mutations, such as exon 21 L861Q, exon 18 G719S, G719A and G719C, exon 20 S768I and V769L). EGFR mutation testing must be performed at participating centres in a certified lab (AIOM-SIAPEC program or other European Quality Assurance [EQA] schemes)
- Clinical or radiologic evidence of disease (at least one target or non target lesion according to RECIST 1.1)
- ECOG performance status 0 to 2
- Life expectancy > 3 months
- Use of an acceptable mean of contraception for men and women of childbearing potential
- Written informed consent.
Exclusion Criteria:
- EGFR T790M mutation alone or exon 20 insertions as unique mutation
- Tumors with a squamous component
- Prior chemotherapy or any other medical treatment for advanced NSCLC (previous neoadjuvant or adjuvant chemotherapy is allowed if > 6 months before randomisation)
- Radiotherapy to any site for any reason within 28 days prior to randomization (palliative radiotherapy to bone lesions is allowed if ≥ 14 days before randomization)
- Full-dose anticoagulation with warfarin
- Current or recent (within 10 days of enrolment) use of aspirin (>325 mg/day) or chronic use of other full-dose nonsteroidal anti-inflammatory drugs (NSAIDs) with anti-platelet activity
- Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P450 3A4 (CYP3A4) are prohibited =< 7 days prior to registration
- Receiving any medications or substances that are inducers of CYP3A4 use of inducers are prohibited =< 7 days prior to registration
-
Inadequate coagulation parameters:
- activated partial thromboplastin time (APTT) >1.5 x the upper limit of normal (ULN) or
- INR >1.5
-
Inadequate liver function, defined as:
- serum (total) bilirubin >1.5 x ULN
- AST/SGOT or ALT/SGPT >2.5 x ULN
-
Inadequate renal function, defined as:
- serum creatinine >2.0 mg/dl or >177 micromol/l
- urine dipstick for proteinuria >2+. Patients with > o = 1+ proteinuria at baseline dipstick analysis must undergo a 24-hour urine collection and must demonstrate ≤1g of protein in their 24-hour urine collection.
- Pregnancy or breast-feeding
- Inadequately controlled hypertension (defined as systolic blood pressure >150 and/or diastolic blood pressure >100 mmHg on antihypertensive medications)
- History of gross hemoptysis within 3 months prior to randomization unless definitively treated with surgery or radiation
- History of any of the following within 6 months prior to randomisation: serious systemic disease, unstable angina, New York Heart Association (NYHA) Grade 2 or greater Congestive Heart Failure (CHF), unstable symptomatic arrhythmia requiring medication, clinically significant peripheral vascular disease, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
- Serious, non-healing wound, ulcer, or bone fracture
- Evidence of bleeding diathesis or coagulopathy or other serious or acute internal bleeding within 6 months prior to randomization
- Central Nervous System (CNS) bleeding; history or clinical evidence of CNS stroke (hemorrhagic or thrombotic) within the last 6 months
- In-patient surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization
- Minor surgical procedure, fine needle aspirations or core biopsy within 7 days prior to randomization
- Anticipation of need for a major surgical procedure during the course of the study
- Inability to take oral medication or requirement for intravenous (IV) alimentation or total parenteral nutrition with lipids, or prior surgical procedures affecting absorption
- Evidence of confusion or disorientation, or history of major psychiatric illness that may impair the patient's understanding of the Informed Consent Form or his/her ability to comply with study requirements
- Any other invasive malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer or surgically resected prostate cancer with normal PSA)
- Brain metastasis
- Patients who have had radiotherapy ≥ 4 weeks prior to the first dose of study treatment, but who are still experiencing acute toxic effects of radiotherapy
- Known HIV positive patients (patients with both acute or chronic infection are excluded)
- Active HBV or HCV infection (patients with chronic non-active infection are eligible)
- Any already known inflammatory changes of the surface of the eye at baseline
- Any other concomitant pathologies or laboratory alterations that prevent or contraindicate the use of erlotinib or bevacizumab.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02633189
Locations
Show 55 study locations
Sponsors and Collaborators
National Cancer Institute, Naples
Investigators
| Principal Investigator: | Cesare Gridelli, M.D. | S.G.Moscati Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | National Cancer Institute, Naples |
| ClinicalTrials.gov Identifier: | NCT02633189 |
| Other Study ID Numbers: |
BEVERLY 2015-002235-17 ( EudraCT Number ) |
| First Posted: | December 17, 2015 Key Record Dates |
| Last Update Posted: | March 24, 2023 |
| Last Verified: | March 2023 |
Keywords provided by National Cancer Institute, Naples:
|
stage IV stage IIIB EGFR mutation non-squamous |
liquid biopsy erlotinib bevacizumab |
Additional relevant MeSH terms:
|
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Bevacizumab Erlotinib Hydrochloride |
Antineoplastic Agents, Immunological Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Tyrosine Kinase Inhibitors Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |